

BETTER IS POSSIBLE.

JP Morgan 43rd Annual Healthcare Conference

Frank D. Lee Chief Executive Officer

PCRX | January 15, 2025

Forward-looking statements and where to find additional information

Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "believes," "anticipates," "plans," "estimates," "expects," "intends," "may," "will," "would," "could," "can" and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to '5x30', our growth and business strategy, our future outlook, contributions of new executives, our intellectual property and patent terms, our future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL. ZILRETTA and iovera[®] and our ability to serve those markets; our plans to expand the use of EXPAREL. ZILRETTA and iovera[®] to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome ("pMVL") drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the ability to successfully integrate any future acquisitions into our existing business; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program: and factors discussed in the "Risk Factors" of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the "SEC").

In addition, the forward-looking statements included in this presentation represent our views as of the date of this presentation. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

When a patient is in pain, their world gets smaller. Our goal is to remove the constraints that pain imposes.



MISSION

We deliver innovative, non-opioid pain therapies to transform the lives of patients.

Frank D. Lee Chief Executive Officer & Director



Strong execution in 2024 has set the foundation for sustainable success in 2025 and beyond



Achieved FY2024 revenue guidance



Secured EXPAREL & iovera^o reimbursement under NOPAIN



Obtained FDA RMAT designation for PCRX-201 & presented compelling 2-year data from robust Phase 1 study



Established commercial, medical & market access powerhouse

Abbreviations: FY, full-year; FDA, Food and Drug Administration; RMAT, Regenerative Medicine Advanced Therapy

We enter 2025 with a clear corporate mission, guiding principles, values...

GUIDING PRINCIPLES



Keep the patient at the center



Follow the science



Treat our people well

VALUES

- Every day, we are determined to achieve the extraordinary
- Integrity is the foundation of who we are
- We respect diverse talent and the collective power of a unified team

...a disciplined growthoriented plan, and a commercial, medical and market access powerhouse.

Frank D. Lee Chief Executive Officer & Director

5x30 path to growth & value creation

ACCELERATING GROWTH IN BASE BUSINESS

- Patients: More than **3 million** patients treated per year
- 2 Product revenue: Double-digit compounded annual growth rate
 - Profitability: 5-percentage point gross margin improvement over 2024

ADVANCING PIPELINE VALUE

4

Pipeline: Clinical pipeline expansion with **5 novel programs** in development

5 |

Partnerships: Establishing **5 partnerships** including pipeline and commercial agreements

5x30 path to growth & value creation

ACCELERATING GROWTH IN BASE BUSINESS

- Patients: More than **3 million** patients treated per year
- 2 Product revenue: Double-digit compounded annual growth rate
 - Profitability: 5-percentage point gross margin improvement over 2024

ADVANCING PIPELINE VALUE



Pipeline: Clinical pipeline expansion with **5 novel programs** in development




Partnerships: Establishing **5 partnerships** including pipeline and commercial agreements

Best-in-class non-opioid commercial portfolio addressing significant unmet needs



EXPAREL

The market's leading long-acting, local analgesic for postsurgical pain





ZILRETTA

The only FDA-approved extended-release IA injection for 3 months of OA knee pain





Market Procedures

¹FY2023 IQVIA Market Procedural Data; IQVIA EXPAREL Utilization Data Triangulated With Pacira Internal Sales Data. ²FY2023 IQVIA Market Procedural Data; ZILRETTA SOB (Source of Business) Utilization Data Triangulated With Pacira Internal Sales Data. ³FY2023 IQVIA Market Procedural Data; Spasticity Patient Model; Secondary Market Research; Pacira Internal Sales Utilization Data. Abbreviations: IA, intra-articular.



ioveraº

The only novel, handheld device for immediate, long-lasting, drug-free pain control using advanced cold technology

Lower Back Pain Foot & Ankle Chronic Severe OA Pain Spasticity Knee Arthroplasty Spine Rib Fracture (Intercostal)



pacira. Better is possible.

NOPAIN: Expected to significantly expand access to EXPAREL and iovera° by overcoming flaws in bundled payments

EXPAREL and iovera[°] are among the 11 drugs and devices qualifying for separate payment via NOPAIN

Flaws of bundled payments for surgical procedures


- Impedes patient and provider access to best-practice pain management by incentivizing the use of cheaper, generic approaches that often incorporate opioids
- Separate reimbursement at ASP+6% eliminates the cost barriers

Patient-centric legislative solution


- Founding of Voices for Non-Opioid Choices—a nonpartisan coalition dedicated to preventing addiction before it starts by improving access to non-opioid options for acute pain
- NOPAIN Act signed into law in 2023

Opportunity to greatly expand patient access

Reimbursement pathway for **18M** surgical procedures in HOPD and ambulatory settings¹



Strong base business with significant growth potential



¹See non-GAAP disclosure in appendix for reconciliation to GAAP.

²Pacira began recognizing ZILRETTA sales upon completing its acquisition of Flexion in November 2021. ³Pacira began recognizing sales of iovera[°] in April 2019 after completing its acquisition of MyoScience, Inc. ⁴Preliminary and unaudited.

Abbreviations: CAGR, compouned annual growth rate; HCP, healthcare practioner.

5x30 path to growth & value creation

ACCELERATING GROWTH IN BASE BUSINESS

- Patients: More than 3 million patients treated per year
- **Product revenue: Double-digit** compounded annual growth rate
- **3 Profitability: 5-percentage point** gross margin improvement over 2024

ADVANCING PIPELINE VALUE


4

Pipeline: Clinical pipeline expansion with **5 novel programs** in development

5 |

Partnerships: Establishing **5 partnerships** including pipeline and commercial agreements

Uniquely positioned to deliver better outcomes across the patient journey



¹Potential duration as product is not FDA approved. Abbreviations: OA, osteoarthritis.


Key data catalysts expected to begin in 2026

Product	Target	2025	2026	2027+	
Innovative Pipel	ine				
PCRX-201	Knee OA	Phase 2 Clinical	Trial: Part A 20	26: Phase 2 topline	
			Phas	e 2 Clinical Trial: Part B	
Commercial Bas	se l	· · · · · · · · · · · · · · · · · · ·			
EXPAREL® (tupiacaine liposome injectable suspension)	Pediatric 0 to <6		PK/Safety Clinical Trial		
	Intrathecal	Phase 1 Clinical Trial			
Zilcetta: Iramindone actionile ectendor release injectable sespension 32 mj	Shoulder OA	Registration Clinical Trial	2026: Phase 3 top	line	
iovera.°	Spasticity	Registration Clinical Trial	2026: Phase 3 top	line	
	New SmartTip for Medial Branch Block (low back pain)	1Q25: Commercial launch			

Abbreviations: PK, pharmacokinetics.

Enekinragene inzadenovec (PCRX-201) has the potential to transform osteoarthritis (OA) treatment

A first-of-its-kind, locally-administered gene therapy for the treatment of common diseases like OA



High unmet need in OA with no new modalities approved in over 20 years


Osteoarthritis: A serious disease of significant and growing economic burden that is starved for innovation



2M Are under 45 years of age



Patients suffering from knee OA say it impacts²




PCRX-201 could represent a revolution in OA treatment, addressing a validated root cause of disease and providing patients relief for years *rather than months*

¹Orthobiologic approaches are not FDA approved.

²www.multivu.com/players/English/9104351-pacira-iovera-knee-pain-survey.

Abbreviations: CS, Corticosteroids; D, day; HA, hyaluronic acids; IA, intra articular; M, month; NSAID, nonsteroidal anti-inflammatory drug; TKA, total knee arthroplasty; Y, year.


PCRX-201 is locally administered to boost IL-1Ra production by the joint cells in the knee in response to inflammation



Abbreviations: IL-1R, IL-1 receptor

>70% of patients saw a >50% improvement in pain and stiffness vs. baseline at week 16 and 78

Data presented at ACR 2024 (Cohen et. al.):



_

- 72 adult patients aged 30 to 80 with moderate to severe OA
- Two three-dose cohorts: co-administered intra-articular steroid cohort and a cohort that did not receive a steroid
 - Doses: 1.4×10¹⁰ GC (low); 1.4×10¹¹ GC (mid); 1.4×10¹² GC (high)
 - Well tolerated with most common AE dose-dependent, transient knee effusion

¹Data from steroid pretreated cohort.

²Review of available literature shows ~1.0-2.5-point reduction in WOMAC scale attributable to placebo effect. Most studies go out to 12-24 weeks; very limited data available at 12-24 months. Abbreviations: AE, adverse event; GC, genome copies; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; ACR, American College of Rheumatology.


- Unprecedented pain relief and durability across all levels of disease severity

Well tolerated with most common AE dose-dependent, transient knee effusion

for at least 2 years from a single injection

Greatest efficacy in co-administered steroid group

PCRX-201 has the potential to be a pipeline within a product





Potential diseasemodifying platform



Localized administration



Addressing prevalent diseases of high unmet need



Attractive cost of goods profile

Disciplined capital allocation strategy to drive shareholder value

ΠΠΠ

Accelerating growth in base business

- Established commercial, medical & market access powerhouse
- Life cycle management programs in areas of high unmet need with favorable return on invested capital
- Educating patients and providers

Section 2 Advancing pipeline value

- Therapeutic area focus on musculoskeletal pain and adjacencies
 - Large market, high unmet need and lacking innovation to date
 - Prioritize mid-to-late-stage/derisked opportunities with validated MOAs and established reimbursement pathway
 - PCRX-201 for Knee OA and adjacencies

Balance sheet management

- Convertible notes maturing in 2025 and 2029, total of \$480M¹
 - Strong cash balance and significant cash flow generation provides optionality for upcoming debt maturities
- Resourcefully leverage debt financing (Term Loan A, total of \$108M¹)

Return capital to shareholders

- Investment in growth with disciplined return of capital to shareholders
 - \$125mm available on share repurchase plan

¹As of 9/30/2024. Abbreviations: MOA, mechanism of action.

(8)

We are transitioning into an innovative biopharmaceutical organization and intend to become the therapeutic area leader in musculoskeletal pain and adjacencies

5x30 path to long-term value creation

ACCELERATING GROWTH IN BASE BUSINESS

- **Patients:** More than **3 million** patients treated per year
- 2 Product revenue: Double-digit compounded annual growth rate
 - Profitability: 5-percentage point gross margin improvement over 2024

ADVANCING PIPELINE VALUE

4

Pipeline: Clinical pipeline expansion with **5 novel programs** in development



Partnerships: Establishing **5 partnerships** including pipeline and commercial agreements



BETTER IS POSSIBLE.

Investor Contact:

investor@pacira.com









APPENDIX

Seasoned executive leadership team



CEO Forma Therapeutics 13+ years Genentech/Roche 13+ years Novartis/Janssen/Lilly

🎸 forma Genentech



Lee Chief Executive Officer & Director



20+ vears Quintiles Transnational organization (now IQVIA) 30+ years commercial leadership experience

 \mathbf{O} QUINTILES





3 years Bioenvision Inc. 5 years Paul Hastings LLP Bioenvision PAUL

6+ years Acadia Pharmaceuticals

11+ years Amgen/TESARO/RainTree

13+ vears Johnson & Johnson

ACADIA Johnson Johnson

TESARO AMGEN RainTree



20 years board-certified anesthesiologist

Cleveland Clinic TEAMHealth.

10+ years Genentech/Roche

Genentech Roche

ORIC

4+ years Lyell Immunopharma

2+ years ORIC Pharmaceuticals

Lvèll

Jonathan Slonin Chief Medical Officer



20+ years biopharmaceutical investment banking experience APPLIED | MOLECULAR | TRANSPORT





14+ years Actavis 4+ years Akorn Inc. 4+ years Alvogen Inc. Actavis OAKORN CAlvogen

Christopher Young Chief Manufacturing Officer



7+ years Patton Boggs LLP 6+ years The Okonite Company SQUIRES O THE PATTON BOGGS

Anthony Molloy Chief Legal & Compliance Officer



Chief Commercial



Krys Corbett Chief Business Officer

Michael Rozycki SVP, Regulatory Affairs



Refreshed board of directors with diversified talent



12+ years

Non-GAAP disclosure

		Year Ended December 31,				
(\$ in 000's)	2019	2020 145,523	2021 41,980	2022 15,909	2023 41,955	
GAAP net income (loss)	(11,016)					
Interest income	(7,376)	(4,629)	(896)	(4,542)	(11,444)	
Interest expense ⁽¹⁾	23,628	25,671	31,750	39,976	20,306	
Income tax (benefit) expense	268	(125,434) ⁽²⁾	14,424 ⁽³⁾	(2,607)	19,746	
Depreciation expense	13,873	12,042	14,995	34,213	18,286	
Amortization of acquired intangible assets	5,703	7,866	13,553	57,288	57,288	
EBITDA	25,080	61,039	115,806	140,237	146,137	
Other adjustments: Contingent consideration (gains) charges, acquisition-related charges, and other:						
Severance-related expenses	-	-	-	4,494	-	
Acquisition-related charges, product discontinuation and other $^{(4)}$	25,230	5,166	42,911	5,546	1,963	
Changes in fair value of contingent consideration	-	-	-	(29,476)	(3,424)	
Restructuring charges	-	-	-	-	1,109	
Impairment of acquired IPR&D	-	-	-	26,134	-	
Termination of license agreement	-	-	-	3,000	-	
Milestone revenue	-	-	(125)	-	-	
Stock-based compensation	33,650	39,920	42,246	48,092	47,895	
Loss on early extinguishment of debt	-	8,071	-	-	16,926	
Recognition of step-up basis in inventory from acquisition	220	-	581	4,719	3,884	
Loss (gain) on investment	4,981	(1,618)	2,585	10,000	-	
Adjusted EBITDA	89,161	112,578	204,004	212,746	214,490	

Notes:

⁽¹⁾ Includes amortization of debt discount.

⁽²⁾ Includes the reversal of a deferred tax valuation allowance during the year ended December 31, 2020.

⁽³⁾ Includes an income tax benefit in connection with the acquisition of Flexion Therapeutics, Inc. during the three months and year ended December 31, 2021.

⁽⁴⁾ Excludes any depreciation expense included in EBITDA above.